Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Andrew Haydon"'
Autor:
Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long
Publikováno v:
The Lancet Oncology. 22:836-847
Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determin
Publikováno v:
Oncologist
Perioperative chemotherapy is standard treatment for patients with early high‐risk gastroesophageal adenocarcinoma independent of molecular subtype. Approximately 8% of gastroesophageal cancers have a microsatellite instable phenotype (MSI‐H), an
Autor:
Michael Millward, V. Atkinson, Sandip Pravin Patel, Christoph Hoeller, Christian U. Blank, Andrew Haydon, Alexander N. Shoushtari, Reinhard Dummer, Alexander M. Menzies, James Larkin, Carina N. Owen, Arissa Young, Maartje W. Rohaan, Dharmisha Chauhan, Shahneen Sandhu, Douglas B. Johnson, J. Mangana, Georgina V. Long, D. Palmieri, Matteo S. Carlino, Serigne Lo, Muhammad A. Khattak, Farzana Y Zaman, Peter Hersey, Belinda Lee
Publikováno v:
Ann Oncol
Background: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%-30% of patients recur within 1 year. This study describes the pattern of recurrence,
Autor:
Prachi Bhave, Andrew Haydon
Publikováno v:
Australasian Journal of Dermatology. 61:203-209
Stage III melanoma involves regional lymph nodes and/or in-transit or satellite disease, without spread to distant metastatic sites. Stage IIIA melanoma includes a T1a-T2a primary lesion with N1a or N2a nodal involvement, whilst stage IIID melanoma i
Autor:
Adnan Nagrial, David Goldstein, Niall C. Tebbutt, Bert Vogelstein, Joshua D. Cohen, Lu Li, Andrew Haydon, Kenneth W. Kinzler, Koen Simons, Peter Gibbs, Jeanne Tie, Cristian Tomasetti, D W M Tai, Prasad Cooray, Nick Papadopoulos, C L Wolfgang, Matthew Burge, Lara Lipton, Belinda Lee, Mehrdad Nikfarjam, Ammar A. Javed, Marion Harris, Benjamin N. J. Thomson, A M Lennon, B. Lawrence
Publikováno v:
Annals of Oncology. 30:1472-1478
In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to info
Autor:
John Zalcberg, John J McNeil, Jessica E. Lockery, Anne Murray, Suzanne G Orchard, Galina Polehkina, Rory Wolfe, Mark Nelson, Robyn L. Woods, Peter Gibbs, Brenda Kirpach, Christopher M. Reid, Andrew Haydon
Publikováno v:
International Journal of Epidemiology. 50
Background The ASPirin in Reducing Events in the Elderly (ASPREE) study randomised healthy older individuals to 100mg aspirin or placebo, with clinical outcomes and disability-free survival endpoints. Detailed baseline data provides a rare opportunit
Autor:
B. Mark Smithers, Andrew Haydon, Rachel Roberts-Thomson, Richard C. W. Martin, Robyn P. M. Saw, John F. Thompson, Victoria Atkinson, David E. Gyorki
Publikováno v:
ANZ journal of surgeryREFERENCES. 91
Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care p
Autor:
James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
Publikováno v:
Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020
European Journal of Cancer, 116, 148-157
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020
European Journal of Cancer, 116, 148-157
Background: The American Joint Committee on Cancer-8 (AJCC) classification of melanoma was implemented in January 2018. It was based on data gathered when checkpoint inhibitors were not used as adjuvant therapy in stage III melanoma. The European Org
Autor:
Michelle Frances Morris, Andrea Harkin, Martin R. Stockler, Eva Segelov, Timothy Iveson, Christine Aiken, Niall C. Tebbutt, Prunella Blinman, David Boadle, Andrew Haydon, Andrew J. Martin, David Goldstein, Michael Jefford
Publikováno v:
JNCI Cancer Spectrum
Background SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients’ preferences for 3 months vs 6 months of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ec577da178882f0af2cfb5e452f04c
Autor:
Katy K. Tsai, Ines Pires da Silva, Andrew Haydon, Rebecca A. Burrell, Adriana Hepner, Serigne Lo, Oliver Klein, James Larkin, Matteo S. Carlino, Megan Lyle, Camille L. Gerard, Alexander M. Menzies, Lisa Zimmer, Lalit Pallan, Victoria Atkinson, Georgina V. Long, Prachi Bhave, Douglas B. Johnson, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 153
Purpose Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resist